Ontology highlight
ABSTRACT:
SUBMITTER: Procopio G
PROVIDER: S-EPMC3491759 | biostudies-literature | 2012 Dec
REPOSITORIES: biostudies-literature
Therapeutic advances in urology 20121201 6
The molecular-targeted agent sorafenib is the first anticancer agent able to slow the progression of advanced/metastatic renal cell carcinoma, a tumor that was formerly refractory to conventional therapy. Experience from everyday clinical practice and investigations exploring the suitability of this agent for patients with harmful pathological conditions has extended the use of sorafenib to other settings of renal cell carcinoma and to particular risk populations. The aim of this review is to pr ...[more]